EBS

Emergent BioSolutions Inc. [EBS] Stock Forecast

Q: What is Emergent BioSolutions Inc. stock symbol ?

Emergent BioSolutions Inc. is a US stock, located in Gaithersburg of Md and trading under the symbol EBS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

EBS Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

EBS has less than 1 year of cash runway

Debt-to-Equity ratio of 1.33 is considered moderate, deeper research suggested.

Top 10 Correlated ETFs

EBS

Top 10 Correlated Stocks

EBS

In the News

EBS Financial details

Company Rating

Buy

Market Cap

107.54M

Income

-759.7M

Revenue

1.05B

Book val./share

12.51

Cash/share

2.15

Dividend

Dividend %

Employees

1.6K

Optionable

Shortable

Yes

Earnings

07 May 2024

P/E

-0.14

Forward P/E

PEG

-0.01

P/S

0.1

P/B

0.15

P/C

0.94

P/FCF

-0.55

Quick Ratio

0.46

Current Ratio

0.53

Debt / Equity

1.33

LT Debt / Equity

0.69

EPS (TTM)

-14.88

EPS next Y

EPS next Q

EPS this Y

232.21%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

-1.05%

Revenue Q/Q

2.26%

EPS Q/Q

-81.48%

SMA20

SMA50

SMA100

Inst Own

62.67%

Inst Trans

0.69%

ROA

-42%

ROE

-75%

ROC

-0.6%

Gross Margin

33%

Oper. Margin

-67%

Profit Margin

-72%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.42-12.87

52W High

-83.21%

52W Low

+101.5%

RSI

Rel Volume

0.22

Avg Volume

3.07M

Volume

689.21K

Perf Week

-7.99%

Perf Month

-25.09%

Perf Quarter

0.75%

Perf Half Y

-19.72%

Beta

1.193

Volatility

0.07%, 0.23%

Prev Close

8.33%

Price

2.015

Change

6.05%

EBS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	21.48	29.51	33.51	22.37	20.49
Net income per share	1.06	5.8	4.1	-4.47	-14.85
Operating cash flow per share	3.65	10.17	6	-0.68	-4.03
Free cash flow per share	1.96	7.5	1.8	-2.99	-5.04
Cash per share	3.26	11.79	10.77	13	2.18
Book value per share	21.14	27.46	30.26	27.6	12.68
Tangible book value per share	1.51	9.81	14.76	8.7	1.62
Share holders equity per share	21.14	27.46	30.26	27.6	12.68
Interest debt per share	16.5	17.19	16.36	28.8	18.76
Market cap	2.78B	4.72B	2.33B	591.68M	122.88M
Enterprise value	3.42B	4.98B	2.59B	1.35B	888.68M
P/E ratio	50.98	15.44	10.6	-2.64	-0.16
Price to sales ratio	2.51	3.04	1.3	0.53	0.12
POCF ratio	14.78	8.81	7.24	-17.35	-0.6
PFCF ratio	27.48	11.95	24.2	-3.95	-0.48
P/B Ratio	2.55	3.26	1.44	0.43	0.19
PTB ratio	2.55	3.26	1.44	0.43	0.19
EV to sales	3.09	3.2	1.45	1.21	0.85
Enterprise value over EBITDA	15.11	9	5.04	-39.39	-20.72
EV to operating cash flow	18.2	9.28	8.07	-39.73	-4.31
EV to free cash flow	33.85	12.6	26.96	-9.04	-3.45
Earnings yield	0.02	0.06	0.09	-0.38	-6.19
Free cash flow yield	0.04	0.08	0.04	-0.25	-2.1
Debt to equity	0.75	0.6	0.52	1.02	1.33
Debt to assets	0.35	0.3	0.28	0.44	0.47
Net debt to EBITDA	2.84	0.46	0.51	-22.19	-17.85
Current ratio	3.17	3.11	3.4	0.98	1.04
Interest coverage	2.97	13.86	10.22	-4.45	-1.78
Income quality	3.45	1.76	1.39	0.15	0.27
Dividend Yield	0	0	0.01	0.01	0
Payout ratio	0.01	0.06	0.07	-0.02	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.2	0.15	0.13	0.17	0.1
Intangibles to total assets	0.43	0.32	0.28	0.3	0.31
Capex to operating cash flow	-0.46	-0.26	-0.7	3.4	0.25
Capex to revenue	-0.08	-0.09	-0.13	-0.1	-0.05
Capex to depreciation	-0.79	-1.23	-1.82	-0.81	-0.4
Stock based compensation to revenue	0.02	0.03	0.02	0.04	0.02
Graham number	22.43	59.87	52.85	52.67	65.1
ROIC	0.04	0.14	0.1	-0.06	-0.12
Return on tangible assets	0.04	0.16	0.1	-0.1	-0.6
Graham Net	-14.67	-9.26	-7.15	-16.72	-14.96
Working capital	469.9M	811.4M	898.3M	-19.2M	28.2M
Tangible asset value	78M	517.2M	789.5M	436M	82.7M
Net current asset value	-554.6M	-240.3M	-67.9M	-572.9M	-506.1M
Invested capital	0.75	0.6	0.52	1.02	1.33
Average receivables	273.2M	253.1M	252.8M	216.55M	174.7M
Average payables	87.75M	115.45M	132.5M	116.2M	107.85M
Average inventory	214.15M	264.75M	328.9M	351.3M	340.35M
Days sales outstanding	90.85	54.18	55.93	51.58	66.44
Days payables outstanding	79.82	94.8	62.11	54.46	54.11
Days of inventory on hand	187.34	213.85	169.03	185.1	158.63
Receivables turnover	4.02	6.74	6.53	7.08	5.49
Payables turnover	4.57	3.85	5.88	6.7	6.75
Inventory turnover	1.95	1.71	2.16	1.97	2.3
ROE	0.05	0.21	0.14	-0.16	-1.17
Capex per share	-1.69	-2.68	-4.21	-2.31	-1.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	6.63	3.29	6.66	5.22	5.33
Net income per share	-1.76	-3.65	-5.15	-5.13	-0.95
Operating cash flow per share	1.86	-3.67	-2.26	1.16	0.62
Free cash flow per share	1.39	-3.97	-2.5	0.92	0.4
Cash per share	13.05	8.69	1.75	1.69	2.15
Book value per share	27.72	23.96	18.86	13.46	12.51
Tangible book value per share	8.74	7.48	2.87	2.21	1.59
Share holders equity per share	27.72	23.96	18.86	13.46	12.51
Interest debt per share	28.43	28.21	18.38	17.02	17.07
Market cap	589.32M	520.07M	372.65M	176.12M	124.56M
Enterprise value	1.35B	1.49B	1.19B	501.92M	890.36M
P/E ratio	-1.67	-0.71	-0.36	-0.17	-0.63
Price to sales ratio	1.78	3.15	1.1	0.65	0.45
POCF ratio	6.35	-2.83	-3.26	2.94	3.88
PFCF ratio	8.52	-2.61	-2.94	3.72	6.02
P/B Ratio	0.43	0.43	0.39	0.25	0.19
PTB ratio	0.43	0.43	0.39	0.25	0.19
EV to sales	4.09	9.01	3.51	1.86	3.22
Enterprise value over EBITDA	-84.01	-13.7	27.55	-45.63	-78.1
EV to operating cash flow	14.57	-8.09	-10.38	8.37	27.74
EV to free cash flow	19.55	-7.47	-9.36	10.59	43.01
Earnings yield	-0.15	-0.35	-0.7	-1.51	-0.4
Free cash flow yield	0.12	-0.38	-0.34	0.27	0.17
Debt to equity	1.02	1.16	0.94	1.24	1.33
Debt to assets	0.44	0.47	0.41	0.46	0.47
Net debt to EBITDA	-47.4	-8.92	18.9	-29.62	-67.18
Current ratio	0.98	1	1.12	0.53	1.04
Interest coverage	-4.56	-8.27	-10.24	-12.29	-1.89
Income quality	-1.05	1.01	0.44	-0.23	-0.65
Dividend Yield	0	0	0.02	0	0
Payout ratio	-0.02	0	-0.04	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.17	0.25	0.08	0.06	0.11
Intangibles to total assets	0.3	0.28	0.37	0.31	0.31
Capex to operating cash flow	-0.25	0.08	0.11	-0.21	-0.36
Capex to revenue	-0.07	-0.09	-0.04	-0.05	-0.04
Capex to depreciation	-0.66	-0.44	-0.38	-0.43	-0.37
Stock based compensation to revenue	0.04	0.04	0.02	0.01	0.01
Graham number	33.16	44.33	46.77	39.43	16.39
ROIC	-0.03	-0.06	-0.16	-0.16	-0.02
Return on tangible assets	-0.04	-0.09	-0.19	-0.2	-0.04
Graham Net	-16.79	-20.12	-14.58	-14.84	-14.76
Working capital	-19.2M	5.6M	84.5M	-309.9M	28.2M
Tangible asset value	436M	375.5M	145.3M	114.4M	82.7M
Net current asset value	-572.9M	-525.9M	-444.8M	-841.8M	-506.1M
Invested capital	1.02	1.16	0.94	1.24	1.33
Average receivables	174.85M	157.15M	223M	253.3M	203.75M
Average payables	103.65M	113.85M	116.25M	110.5M	112.45M
Average inventory	449.05M	359.85M	361.1M	354.2M	341.5M
Days sales outstanding	43.11	84.98	77.27	72.03	62.15
Days payables outstanding	42.46	72.07	51.14	57.37	50.04
Days of inventory on hand	144.31	213.48	167.3	180.25	146.68
Receivables turnover	2.09	1.06	1.16	1.25	1.45
Payables turnover	2.12	1.25	1.76	1.57	1.8
Inventory turnover	0.62	0.42	0.54	0.5	0.61
ROE	-0.06	-0.15	-0.27	-0.38	-0.08
Capex per share	-0.47	-0.3	-0.25	-0.24	-0.22

EBS Frequently Asked Questions

What is Emergent BioSolutions Inc. stock symbol ?

Emergent BioSolutions Inc. is a US stock , located in Gaithersburg of Md and trading under the symbol EBS

What is Emergent BioSolutions Inc. stock quote today ?

Emergent BioSolutions Inc. stock price is $2.015 today.

Is Emergent BioSolutions Inc. stock public?

Yes, Emergent BioSolutions Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 3.07M
Market Capitalization 107.54M
Employee 1.6K
CEO Mr. Joseph C. Papa Jr.
Headquarters Gaithersburg,MD,US
IPO Date 2006-11-15
Website https://www.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.